NASDAQ:CRDF
Cardiff Oncology Inc. Stock News
$3.63
-0.110 (-2.94%)
At Close: May 17, 2024
Take the first step towards designing your global career with GANPAT UNIVERSITY - Times of India
04:15am, Thursday, 11'th Jun 2020
Education News: Situated in Mehsana, Gujarat, Ganpat University, is a high-tech university, established as a joint initiative, purely philanthropic in nature, by a la
Nothing To Worry About With PIMCO Taxable CEFs
11:00am, Wednesday, 10'th Jun 2020
We think too much is being made of the lower coverage in the UNII report and that those ratios tend to ebb and flow over time. We do not foresee a distribution
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated
ArcherDX Promises Precision Oncology For All
06:23pm, Sunday, 07'th Jun 2020
Trying to monitor what's happening in the disruptive technology space is a difficult task. We try to keep tabs on any IPO which dabbles in any of the 60 disruptive technology themes we research here a
Singapore Firm Develops Free AI-Digital Marketing Self-Test for SMEs
10:41pm, Tuesday, 02'nd Jun 2020
Jun 02, 2020 (AB Digital via COMTEX) --
Singapore - 2 Jun, 2020 - To help businesses digitally transform in the face of the COVID-19 pandemic, Singapore...
How to Know if You're Actually Getting Dolby Atmos Sound | Digital Trends
12:25pm, Saturday, 30'th May 2020
Dolby Atmos surround sound is the holy grail for home theater lovers who want the best. But getting Dolby Atmos isn't as straightforward as you might think.
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated
Cardiff Oncology : Announces $2.5 Million Equity Investment by Biotech-Focused Fundamental Investor Acorn Bioventures | MarketScreener
12:16pm, Wednesday, 27'th May 2020Cardiff Oncology Announces $2.5 Million Equity Investment by Biotech-Focused Fundamental Investor Acorn Bioventures
12:15pm, Wednesday, 27'th May 2020
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated
The Chemist's Closed-End Fund Report, May 2020: Thoughts On Our Portfolio Strategy And Why We Stay The Course
02:44pm, Monday, 25'th May 2020
We warned about overvalued CEFs in February, although we didn't expect the crash to come so quickly and violently. My thoughts on our portfolio strategy and why
Cardiff Oncology Announces Private Placement Investment by Board of Directors and Chief Executive Officer
12:15pm, Tuesday, 19'th May 2020
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated
What PIMCO Has Done In Terms Of Leverage For Its Taxable Funds
11:02am, Tuesday, 19'th May 2020
We have seen two funds delever significantly in the last two months - PCI and PCM. PKO and PDI have ramped up with increased borrowing. We discuss deleveraging
